Release Details
New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS
New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS
July 10, 2020
IB_NEJM_tofersen study_V2.0.pdf 628.9 KB